Kestra Medical Technologies, Lt (KMTS) Stock Analysis

Kestra Medical Technologies generated $59.8 million in revenue for the fiscal year ended April 30, 2025, up 115% from $27.8 million a year earlier, almost entirely from its ASSURE WCD, a wearable cardioverter defibrillator that received FDA premarket approval on July 27, 2021. The company's commercial efforts remain focused on the U.S. market, where an estimated 285 million insured lives, about 90% of total available lives, are covered for the ASSURE WCD under Medicare, Medicaid, and commercial payor contracts.

Kestra earns revenue primarily by leasing the ASSURE WCD to patients on a month-to-month basis and billing third-party payors — Medicare, Medicaid, and private insurers — directly for wear time, supplemented by patient co-insurance and deductible billing. The device is delivered and fitted by a network of more than 300 contracted patient specialists, supported by roughly 80 direct sales representatives and more than 40 sales and clinical support professionals as of April 30, 2025. Devices are reprocessed and returned to the distribution fleet after each patient's wear period, an asset-reuse model the company says supports unit economics as volume scales. Two pivotal trials, ACE-DETECT and ACE-CONVERT, formed the basis for the ASSURE WCD's premarket approval, and an ongoing post-approval registry, ACE-PAS, had enrolled more than 20,000 patients as of April 30, 2025. The company's only commercial competitor has offered the sole other WCD on the market for more than two decades, a market structure the 10-K frames as a two-player category.